Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

BioMed Research International
Volume 2016, Article ID 1845638, 12 pages
http://dx.doi.org/10.1155/2016/1845638
Research Article

Expression Profiling of Genes Related to Endothelial Cells Biology in Patients with Type 2 Diabetes and Patients with Prediabetes

1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
2Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Received 10 June 2016; Revised 18 August 2016; Accepted 30 August 2016

Academic Editor: Gelin Xu

Copyright © 2016 Sara Moradipoor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Schalkwijk and C. D. A. Stehouwer, “Vascular complications in diabetes mellitus: the role of endothelial dysfunction,” Clinical Science, vol. 109, no. 2, pp. 143–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Félétou, The Endothelium: Part 1: Multiple Functions of the Endothelial Cells—Focus on Endothelium-Derived Vasoactive Mediators, Morgan & Claypool Life Sciences, 2011.
  3. J. Xu and M.-H. Zou, “Molecular insights and therapeutic targets for diabetic endothelial dysfunction,” Circulation, vol. 120, no. 13, pp. 1266–1286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. B. Williams, J. A. Cusco, M.-A. Roddy, M. T. Johnstone, and M. A. Creager, “Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus,” Journal of the American College of Cardiology, vol. 27, no. 3, pp. 567–574, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. H. H. Ting, F. K. Timimi, K. S. Boles, S. J. Creager, P. Ganz, and M. A. Creager, “Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 97, no. 1, pp. 22–28, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zhang, D. Gong, S. Li, and X. Zhou, “Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus,” Atherosclerosis, vol. 223, no. 1, pp. 78–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. K. Kolluru, S. C. Bir, and C. G. Kevil, “Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing,” International Journal of Vascular Medicine, vol. 2012, Article ID 918267, 30 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. V. Diogo, J. M. Suski, M. Lebiedzinska et al., “Cardiac mitochondrial dysfunction during hyperglycemia—the role of oxidative stress and p66Shc signaling,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 1, pp. 114–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Su, X.-M. Liu, Y.-M. Sun, Y.-Y. Wang, Y. Luan, and Y. Wu, “Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus,” The American Journal of Cardiology, vol. 102, no. 4, pp. 497–498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-C. Wu, H.-K. Sytwu, K.-C. Lu, and Y.-F. Lin, “Role of T cells in type 2 diabetic nephropathy,” Experimental Diabetes Research, vol. 2011, Article ID 514738, 9 pages, 2011. View at Publisher · View at Google Scholar
  11. M. F. Brizzi, G. Garbarino, P. R. Rossi et al., “Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells,” The Journal of Clinical Investigation, vol. 91, no. 6, pp. 2887–2892, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Khew-Goodall, C. M. Butcher, M. S. Litwin et al., “Chronic expression of P-selectin on endothelial cells stimulated by the T-Cell cytokine, interleukin-3,” Blood, vol. 87, no. 4, pp. 1432–1438, 1996. View at Google Scholar · View at Scopus
  13. E. I. Korpelainen, J. R. Gamble, W. B. Smith et al., “The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor α and potentiates interleukin 8 secretion and neutrophil transmigration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 23, pp. 11137–11141, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Starkey, S. J. Haidacher, W. S. LeJeune et al., “Diabetes-induced activation of canonical and noncanonical nuclear factor-κB pathways in renal cortex,” Diabetes, vol. 55, no. 5, pp. 1252–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Yu, C. Gong, B. Lu et al., “Dendrobium chrysotoxum Lindl. alleviates diabetic retinopathy by preventing retinal inflammation and tight junction protein decrease,” Journal of Diabetes Research, vol. 2015, Article ID 518317, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, L. F. Leo, C. McGregor, A. Grivitishvili, C. J. Barnstable, and J. Tombran-Tink, “Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice,” Molecular Medicine, vol. 18, pp. 1387–1401, 2012. View at Google Scholar · View at Scopus
  17. S. Hazra, Endothelial Progenitor Cell Dysfunction in Diabetes, University of Florida, Gainesville, Fla, USA, 2011.
  18. A. Ito, N. Aoyanagi, and T. Maki, “Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice,” Journal of Autoimmunity, vol. 10, no. 4, pp. 331–338, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Kan, S. A. Baldwin, and A. D. Whetton, “Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line,” The Journal of Experimental Medicine, vol. 180, no. 3, pp. 917–923, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. K. D. McCoy, N. Ahmed, A. S. Tan, and M. V. Berridge, “The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters,” The Journal of Biological Chemistry, vol. 272, no. 28, pp. 17276–17282, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. H. L. Wieman, J. A. Wofford, and J. C. Rathmell, “Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking,” Molecular Biology of the Cell, vol. 18, no. 4, pp. 1437–1446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. von der Thüsen, J. Kuiper, T. J. C. van Berkel, and E. A. L. Biessen, “Interleukins in atherosclerosis: molecular pathways and therapeutic potential,” Pharmacological Reviews, vol. 55, no. 1, pp. 133–166, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Weisensee, J. Bereiter-Hahn, W. Schoeppe, and I. Löw-Friedrich, “Effects of cytokines on the contractility of cultured cardiac myocytes,” International Journal of Immunopharmacology, vol. 15, no. 5, pp. 581–587, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Priest, A. D. Watts, J. S. Whittaker et al., “Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes,” Google Patents, 2006.
  25. S. Huang, Z. Chen, J. F. Yu et al., “Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues,” STEM CELLS, vol. 17, no. 5, pp. 265–272, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Ganser, A. Lindemann, G. Seipelt et al., “Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure,” Blood, vol. 76, no. 4, pp. 666–676, 1990. View at Google Scholar · View at Scopus
  27. R. E. Donahue, J. Seehra, M. Metzger et al., “Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates,” Science, vol. 241, no. 4874, pp. 1820–1823, 1988. View at Publisher · View at Google Scholar · View at Scopus
  28. M. H. Mangi and A. C. Newland, “Interleukin-3 in hematology and oncology: current state of knowledge and future directions,” Cytokines, Cellular and Molecular Therapy, vol. 5, no. 2, pp. 87–95, 1999. View at Google Scholar · View at Scopus
  29. G. Shatirishvili, K. Mardaleishvili, and G. Loladze, “Cord blood hematopoietic stem cell expansion: preclinical studies and clinical trials. Review,” CellR4: The official Journal of The Cure Alliance, vol. 2, no. 5, article e1209, 2014. View at Google Scholar
  30. S. D. J. M. Kanters, J.-D. Banga, A. Algra, R. C. J. M. Frijns, J. J. Beutler, and R. Fijnheer, “Plasma levels of cellular fibronectin in diabetes,” Diabetes Care, vol. 24, no. 2, pp. 323–327, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Chen, Z. A. Khan, M. Cukiernik, and S. Chakrabarti, “Differential activation of NF-κB and AP-1 in increased fibronectin synthesis in target organs of diabetic complications,” American Journal of Physiology—Endocrinology and Metabolism, vol. 284, no. 6, pp. E1089–E1097, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. A. R. Yaghoubi, F. Kargar, and F. Khaki-Khatibi, “Association of fibronectin, leptin and LDL-oxide serum levels with coronary artery disease in non-smoker and non-diabetic patients,” Crescent Journal of Medical and Biological Sciences, vol. 3, pp. 23–27, 2016. View at Google Scholar
  33. I. Rohwedder, E. Montanez, K. Beckmann et al., “Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation,” EMBO Molecular Medicine, vol. 4, no. 7, pp. 564–576, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. A. K. Death, E. J. Fisher, K. C. Y. McGrath, and D. K. Yue, “High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes,” Atherosclerosis, vol. 168, no. 2, pp. 263–269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Alsaigh, E. S. Pocock, J. J. Bergan, and G. W. Schmid-Schönbein, “Acute venous occlusion enhances matrix metalloprotease activity: implications on endothelial dysfunction,” Microvascular Research, vol. 81, no. 1, pp. 108–116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Alexander and J. W. Elrod, “Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation,” Journal of Anatomy, vol. 200, no. 6, pp. 561–574, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Drzewoski, A. Sliwińska, K. Przybyłowska et al., “Gene polymorphisms and antigen levels of matrix metalloproteinase-1 in type 2 diabetes mellitus coexisting with coronary heart disease,” Kardiologia Polska, vol. 66, no. 10, pp. 1042–1049, 2008. View at Google Scholar
  38. N. Yildirim, A. Sahin, N. Erol, S. Kara, S. Uslu, and S. Topbas, “The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection,” Journal of Glaucoma, vol. 17, no. 4, pp. 253–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Kowluru, “Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras,” Investigative Ophthalmology and Visual Science, vol. 51, no. 8, pp. 4320–4326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. J. Zhou, J. H. Wang, L. Li, H. W. Yang, D. L. Wen, and Q. C. He, “Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability,” Biochemical and Biophysical Research Communications, vol. 363, no. 1, pp. 30–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Cipollone, A. Mezzetti, M. L. Fazia et al., “Association between 5-lipoxygenase expression and plaque instability in humans,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1665–1670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Kenichi, M. Masanobu, K. Takehiko et al., “Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor,” Journal of Laboratory and Clinical Medicine, vol. 144, no. 2, pp. 69–77, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Wojta, R. L. Hoover, and T. O. Daniel, “Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator,” The Journal of Biological Chemistry, vol. 264, no. 5, pp. 2846–2852, 1989. View at Google Scholar · View at Scopus
  44. M. Falkenberg, C. Tom, M. B. DeYoung, S. Wen, R. Linnemann, and D. A. Dichek, “Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10665–10670, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Rajecki, P. Pajunen, P. Jousilahti, V. Rasi, E. Vahtera, and V. Salomaa, “Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK ′92 Hemostasis Study,” Blood Coagulation and Fibrinolysis, vol. 16, no. 2, pp. 119–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. R. Folsom, N. Aleksic, E. Park, V. Salomaa, H. Juneja, and K. K. Wu, “Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 611–617, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Burtea, S. Laurent, O. Murariu et al., “Molecular imaging of αvβ3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA,” Cardiovascular Research, vol. 78, no. 1, pp. 148–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Roth, F. Podestá, M. A. Stepp, D. Boeri, and M. Lorenzi, “Integrin overexpression induced by high glucose and by human diabetes: potential pathway to cell dysfunction in diabetic microangiopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 20, pp. 9640–9644, 1993. View at Publisher · View at Google Scholar · View at Scopus
  49. A. R. Reynolds, L. E. Reynolds, T. E. Nagel et al., “Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice,” Cancer Research, vol. 64, no. 23, pp. 8643–8650, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Ning, J. Cui, D. Maberley, P. Ma, and J. Matsubara, “Expression of integrins in human proliferative diabetic retinopathy membranes,” Canadian Journal of Ophthalmology, vol. 43, no. 6, pp. 683–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Stoynev, I. Dimova, B. Rukova et al., “Gene expression in peripheral blood of patients with hypertension and patients with type 2 diabetes,” Journal of Cardiovascular Medicine, vol. 15, no. 9, pp. 702–709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Huang, X. Q. Liu, S. C. Rall Jr. et al., “Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia,” The Journal of Biological Chemistry, vol. 273, no. 41, pp. 26388–26393, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Leiva, V. Mujica, R. Orrego, M. Prieto, and M. Arredondo, “Apolipoprotein E polymorphism in type 2 diabetic patients of Talca, Chile,” Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 244–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Sigala, G. Vourliotakis, S. Georgopoulos et al., “Vascular endothelial cadherin expression in human carotid atherosclerotic plaque and its relationship with plaque morphology and clinical data,” European Journal of Vascular and Endovascular Surgery, vol. 26, no. 5, pp. 523–528, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. B. W. C. Wong, D. Wong, and B. M. McManus, “Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease,” Cardiovascular Pathology, vol. 11, no. 6, pp. 332–338, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Schäfer, C. Schulz, D. Fraccarollo et al., “The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 55–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Kikuchi, T. Imakiire, T. Hyodo et al., “Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli,” Nephrology Dialysis Transplantation, vol. 20, no. 12, pp. 2690–2696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. K. H. Song, J. Park, J. H. Park, R. Natarajan, and H. Ha, “Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice,” Diabetologia, vol. 56, no. 7, pp. 1661–1669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Zumbach, M. Hofmann, V. Borcea et al., “Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 105, no. 4, pp. 206–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Aso, Y. Fujiwara, K. Tayama, K. Takebayashi, T. Inukai, and Y. Takemura, “Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes,” Clinica Chimica Acta, vol. 301, no. 1-2, pp. 135–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. M. M. Ewing, M. R. de Vries, M. Nordzell et al., “Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 95–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Moore, A. Hawley, R. Sigler et al., “Tissue inhibitor of metalloproteinase-1 is an early marker of acute endothelial dysfunction in a rodent model of venous oxidative injury,” Annals of Vascular Surgery, vol. 23, no. 4, pp. 498–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Derosa, A. D'Angelo, C. Tinelli et al., “Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects,” Diabetes and Metabolism, vol. 33, no. 2, pp. 129–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. T. A. DiMaio, S. Wang, Q. Huang, E. A. Scheef, C. M. Sorenson, and N. Sheibani, “Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice,” Developmental Biology, vol. 315, no. 1, pp. 72–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Randriamboavonjy, F. Pistrosch, B. Bölck et al., “Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and μ-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone,” Circulation, vol. 117, no. 1, pp. 52–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Solowiej, P. Biswas, D. Graesser, and J. A. Madri, “Lack of platelet endothelial cell adhesion molecule-1 attenuates foreign body inflammation because of decreased angiogenesis,” The American Journal of Pathology, vol. 162, no. 3, pp. 953–962, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Thum, A. Haverich, and J. Borlak, “Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology,” The FASEB Journal, vol. 14, no. 5, pp. 740–751, 2000. View at Google Scholar · View at Scopus